The eyes have it: Second Sight shoots for $31.5m, Retina Implant bags German reimbursement
This article was originally published in Clinica
Executive Summary
Activity is heating up in the promising retinal implant space – the devices are designed to help restore vision in patients who have lost their sight. First, “bionic eye” developer Second Sight has priced its initial public offering, with a target of $31.5m; meanwhile, German rival Retina Implant has got reimbursement in its home market for its Alpha IMS microchip.